An Open-label, Randomized Cross-over, Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of Two Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Paclitaxel (Primary) ; HM 30181A
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Athenex
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 Status changed from recruiting to completed, as per results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 12 Jun 2014 Status changed from planning to recruiting as reported by Australian New Zealand Clinical Trials Registry record.